Literature DB >> 11593392

Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer.

S Fulda1, M U Küfer, E Meyer, F van Valen, B Dockhorn-Dworniczak, K M Debatin.   

Abstract

Resistance of tumors to treatment with cytotoxic drugs, irradiation or immunotherapy may be due to disrupted apoptosis programs. Here, we report in a variety of different tumor cells including Ewing tumor, neuroblastoma, malignant brain tumors and melanoma that caspase-8 expression acts as a key determinant of sensitivity for apoptosis induced by death-inducing ligands or cytotoxic drugs. In tumor cell lines resistant to TRAIL, anti-CD95 or TNFalpha, caspase-8 protein and mRNA expression was decreased or absent without caspase-8 gene loss. Methylation-specific PCR revealed hypermethylation of caspase-8 regulatory sequences in cells with impaired caspase-8 expression. Treatment with the demethylation agent 5-Aza-2'-deoxycytidine (5-dAzaC) reversed hypermethylation of caspase-8 resulting in restoration of caspase-8 expression and recruitment and activation of caspase-8 at the CD95 DISC upon receptor cross-linking thereby sensitizing for death receptor-, and importantly, also for drug-induced apoptosis. Inhibition of caspase-8 activity also inhibited apoptosis sensitization by 5-dAzaC. Similar to demethylation, introduction of caspase-8 by gene transfer sensitized for apoptosis induction. Hypermethylation of caspase-8 was linked to reduced caspase-8 expression in different tumor cell lines in vitro and, most importantly, also in primary tumor samples. Thus, these findings indicate that re-expression of caspase-8, e.g. by demethylation or caspase-8 gene transfer, might be an effective strategy to restore sensitivity for chemotherapy- or death receptor-induced apoptosis in various tumors in vivo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11593392     DOI: 10.1038/sj.onc.1204750

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  114 in total

1.  Is caspase-8 a neuroendocrine lung tumor suppressor?

Authors:  Suparna Mazumder; Alexandru Almasan
Journal:  Cancer Biol Ther       Date:  2002 Jan-Feb       Impact factor: 4.742

2.  Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children's Oncology Group study.

Authors:  Rani E George; Jill M Lahti; Peter C Adamson; Kejin Zhu; David Finkelstein; A Mark Ingle; Joel M Reid; Mark Krailo; Donna Neuberg; Susan M Blaney; Lisa Diller
Journal:  Pediatr Blood Cancer       Date:  2010-10       Impact factor: 3.167

Review 3.  Pediatric oncology.

Authors:  Andrew M Davidoff
Journal:  Semin Pediatr Surg       Date:  2010-08       Impact factor: 2.754

4.  Epigenetic aberrant methylation of tumor suppressor genes in small cell lung cancer.

Authors:  Shuai Wang; Zhou Wang
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

5.  CASP8 polymorphisms contribute to cancer susceptibility: evidence from a meta-analysis of 23 publications with 55 individual studies.

Authors:  Ming Yin; Jingrong Yan; Sheng Wei; Qingyi Wei
Journal:  Carcinogenesis       Date:  2010-02-22       Impact factor: 4.944

Review 6.  In search of tumor suppressing functions of menin.

Authors:  Yuqing Yang; Xianxin Hua
Journal:  Mol Cell Endocrinol       Date:  2007-01-11       Impact factor: 4.102

7.  Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents.

Authors:  Bing Z Carter; Po Yee Mak; Duncan H Mak; Yuexi Shi; Yihua Qiu; James M Bogenberger; Hong Mu; Raoul Tibes; Hui Yao; Kevin R Coombes; Rodrigo O Jacamo; Teresa McQueen; Steven M Kornblau; Michael Andreeff
Journal:  J Natl Cancer Inst       Date:  2014-02       Impact factor: 13.506

8.  Smad7 protein induces interferon regulatory factor 1-dependent transcriptional activation of caspase 8 to restore tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis.

Authors:  Suntaek Hong; Hye-Youn Kim; Jooyoung Kim; Huyen Trang Ha; Young-Mi Kim; Eunjin Bae; Tae Hyung Kim; Kang Choon Lee; Seong-Jin Kim
Journal:  J Biol Chem       Date:  2012-12-19       Impact factor: 5.157

9.  Retinoic acid receptor beta2 re-expression and growth inhibition in thyroid carcinoma cell lines after 5-aza-2'-deoxycytidine treatment.

Authors:  F Y Miasaki; A Vivaldi; R Ciampi; L Agate; P Collecchi; A Capodanno; A Pinchera; R Elisei
Journal:  J Endocrinol Invest       Date:  2008-08       Impact factor: 4.256

10.  Aberrant gene expression in human non small cell lung carcinoma cells exposed to demethylating agent 5-aza-2'-deoxycytidine.

Authors:  Bao-Zhu Yuan; Amy M Jefferson; Nicholas C Popescu; Steven H Reynolds
Journal:  Neoplasia       Date:  2004 Jul-Aug       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.